Achieve high-efficiency, stable gene editing using our optimized CRISPR-Cas9 workflows. We support cell lines, iPSCs, and advanced cell models to accelerate discovery and disease research.
Price | 10000€+ |
Organism | Human |
Product Type | Gene Editing |
Tissue | – |
Disease | – |
Applications
Technology Service
CRISPR-Cas9
With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have...
Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...
Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...
We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...
CRISPR-Cas9 is a genome editing technology that enables precise modification of specific genes by targeting defined DNA sequences. It allows researchers to disrupt, insert, or alter genes with high accuracy, supporting disease modeling, functional genomics, and advanced screening in human-relevant cell systems. To achieve reliable and reproducible results, CRISPR workflows must be carefully designed, optimized, and validated – particularly when working with iPSCs or complex cell models.
Lambda Biologics provides reliable CRISPR-Cas9 gene editing services with high editing efficiency, optimized sgRNA design, robust quality control, and proven expertise in iPSC and advanced cell models.
Lambda Biologics’ CRISPR-Cas9 services support a wide range of research and development programs.
Fabry disease is a rare X-linked inherited disorder resulting from a deficiency or absence of the lysosomal enzyme α-galactosidase A (α-Gal A). This deficiency disrupts the glycosphingolipid metabolic pathway, causing the accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids within lysosomes. This accumulation impairs cellular morphology and function, leading to a multisystemic condition associated with severe complications such as stroke, heart failure, cardiac arrhythmia, and end-stage renal disease. Unfortunately, these complications contribute to a reduced life expectancy in individuals with Fabry disease.
Lambda has developed a model for Fabry’s disease, creating kidney organoids through CRISPR-Cas9 gene editing. This model closely mirrors the pathological phenotype of human Fabry disease and responds to enzyme replacement therapy. Consequently, it stands as a valuable tool in the development of treatments for Fabry disease.
Ready to start your CRISPR-Cas9 project?
Contact Lambda Biologics to discuss your target genes and cell models.
We support gene knock-out, knock-in, point mutations, CRISPRi/CRISPRa, and multiplex editing, depending on your research objectives and cell model.
Our services cover immortalized cell lines, primary cells, iPSCs, and complex or organoid-derived cell models.
We apply optimized sgRNA design, controlled delivery methods, and rigorous validation to ensure high specificity and reproducible editing outcomes.
Yes. We perform clone selection, genotypic validation, and quality control to deliver well-characterized edited cell lines when required.
Yes. CRISPR-edited iPSCs can be integrated with downstream differentiation or organoid workflows to support disease modeling and functional studies.
